Detalles de la búsqueda
1.
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
Clin Infect Dis
; 76(10): 1832-1840, 2023 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36645792
2.
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
N Engl J Med
; 381(9): 803-815, 2019 08 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31339677
3.
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
J Antimicrob Chemother
; 77(10): 2706-2712, 2022 09 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35953881
4.
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
J Antimicrob Chemother
; 76(2): 286-291, 2021 01 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33063117
5.
Progress towards antibiotic use targets in eight high-income countries.
Bull World Health Organ
; 99(8): 550-561, 2021 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34354310
6.
Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey.
Thorax
; 75(12): 1082-1088, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32796119
7.
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
J Antimicrob Chemother
; 75(11): 3373-3378, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32812025
8.
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.
J Antimicrob Chemother
; 75(11): 3379-3385, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32812039
9.
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
J Antimicrob Chemother
; 75(11): 3366-3372, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32812051
10.
Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition.
Clin Infect Dis
; 68(1): 87-95, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29771285
11.
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
PLoS Med
; 16(9): e1002895, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31539371
12.
Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda.
BMC Infect Dis
; 17(1): 315, 2017 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28464899
13.
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
Clin Infect Dis
; 62(6): 683-694, 2016 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26787172
14.
Erratum Erratum to: Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
J Antimicrob Chemother
; 76(6): 1653, 2021 May 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33704468
15.
Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.
Hepatology
; 61(4): 1174-82, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25482139
16.
Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.
Clin Infect Dis
; 61(5): 730-40, 2015 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25987643
17.
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Clin Infect Dis
; 58(7): 928-36, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24399087
18.
Defining a malaria diagnostic pathway from innovation to adoption: Stakeholder perspectives on data and evidence gaps.
PLOS Glob Public Health
; 4(5): e0002957, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38753739
19.
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens.
Open Forum Infect Dis
; 11(3): ofae007, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38529213
20.
Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial.
Trials
; 25(1): 311, 2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38720383